Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for UDG Healthcare in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 1,079.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in UDG Healthcare. This rating has held steady since July 2022, when it changed from a Hold consensus rating.
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services. This segment supports healthcare professionals and patients at various stages of the product life cycle; and provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies. The Sharp segment provides contract and clinical trial packaging services for the pharmaceutical and biotechnology industries; serialization solutions; and clinical IRT services. The company was formerly known as United Drug plc and changed its name to UDG Healthcare plc in August 2013. UDG Healthcare plc was founded in 1948 and is heaquartered in Dublin, the Republic of Ireland.